Printer Friendly

Pfizer Presents Overall Survival Data of Xalkori in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.

M2 PHARMA-September 11, 2017-Pfizer Presents Overall Survival Data of Xalkori in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer

(C)2017 M2 COMMUNICATIONS

- US-based pharmaceutical company Pfizer Inc. (NYSE: PFE) has released final overall survival data from the PROFILE 1014 trial examining Xalkori (crizotinib) in previously untreated patients with ALK-positive advanced non-small cell lung cancer(NSCLC), the company said.

After a median follow-up of 46 months, the median OS for patients randomised to Xalkori was not reached (95% CI: 45.8 months, not reached) and was 47.5 months for patients randomized to chemotherapy (95% CI:32.2 months, not reached).

Results indicated a numerical improvement in OS for patients treated with first-line Xalkori compared with chemotherapy, though this difference did not quite achieve statistical significance (HR=0.760 [95% CI: 0.548, 1.053]; p=0.0978).

These data [Abstract #LBA50] were presented TODAY at the 2017 European Society for Medical Oncology Congress in Madrid, Spain.

The majority of patients initially randomised to chemotherapy received Xalkori after they progressed and this likely affected the overall survival results.

A pre-specified, exploratory statistical analysis, adjusting for the effects of crossover, determined that median OS would have been longer for patients randomized to Xalkori than for patients randomised to chemotherapy, if patients had not been allowed to cross over [HR: 0.346 (95% CI: 0.081, 0.718)].

Overall survival was a secondary endpoint of PROFILE 1014 and the threshold for statistical significance was p<=0.0247.

PROFILE 1014 was a global, randomized, open-label, two-arm Phase 3 study that evaluated the efficacy and safety of XALKORI in patients with previously untreated ALK-positive advanced NSCLC.

Progression-free survival was the primary endpoint, and these results were previously published in The New England Journal of Medicine.

There was a statistically significant improvement in PFS in the patients treated with XALKORI than with chemotherapy (p

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 11, 2017
Words:320
Previous Article:Ozmosi Launches a Global Clinical Trials Database.
Next Article:First Human Patient Treated with AmpliPhi Biosciences' AB-SA01 Targeting Staphylococcus Aureus.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters